A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
Administered By
Awarded By
Contributors
- Onken, Jane Elizabeth Principal Investigator
Start/End
- January 20, 2021 - January 17, 2024